Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries.

Sendhil SR, Cadarette SM, Aggarwal S, Oganisian A, Zullo AR, Berry SD, Adegboye MA, Hayes KN

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA27 Oct 2025Cited by 2 (Europe PMC)

PMID41143882PMCIDPMC12744900DOI10.1007/s00198-025-07668-xPepBankPUB-41143882

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among Medicare beneficiaries stopping denosumab, 4912 (6.0%) initiated pooled follow-on therapies that included abaloparatide.
In plain wordsAfter denosumab stopped, 6.0% of patients started another osteoporosis treatment from a group that included abaloparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableFollow-on osteoporosis therapy initiation
Study
n = 82,519
Outcome group
Patterns of use · Musculoskeletal
Measurements
Follow-on therapy initiation
4912 patients
Within 1 year
Follow-on therapy initiation
6%
Within 1 year
Source sentences
Summary
Only 4912 (6.0%) individuals initiated follow-on therapy after discontinuation; mean time from discontinuation (last claim + 243 days) to follow-on therapy initiation was 3.3 months [SD = 3.4].
1 context sentence(design, population, supporting numbers)
Summary · context
During follow-up through 2022, we identified beneficiaries with follow-on osteoporosis therapy (i.e., oral and intravenous bisphosphonates, teriparatide, and abaloparatide) within 1 year after denosumab discontinuation.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4114388201
02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Younger age versus ≥ 85 years, female sex, prior osteoporosis therapy, and 1-2 denosumab claims predicted pooled follow-on therapy initiation versus none.
In plain wordsSeveral patient characteristics were linked to starting pooled osteoporosis treatments, including abaloparatide, compared with no further therapy.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedPredictors of pooled follow-on therapy
Study
n = 82,519
Comparator
No follow-on therapy
Outcome group
Patterns of use · Musculoskeletal
Source sentences
Summary
Younger age (vs. ≥ 85 years), female sex, prior osteoporosis therapy, and Having 1-2 denosumab claims (vs. longer therapy) before discontinuation were strong predictors of follow-on therapy initiation versus no follow-on therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
During follow-up through 2022, we identified beneficiaries with follow-on osteoporosis therapy (i.e., oral and intravenous bisphosphonates, teriparatide, and abaloparatide) within 1 year after denosumab discontinuation.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4114388203
03HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther
Among Medicare beneficiaries stopping denosumab, mean time to pooled follow-on therapy was 3.3 months after the defined discontinuation date.
In plain wordsPatients who started another treatment from a group including abaloparatide waited an average of 3.3 months after the defined discontinuation date.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTime to pooled follow-on therapy
Study
n = 4,912
Outcome group
Patterns of use · Musculoskeletal
Measurements
Mean time to follow-on therapy
3.3 months
From defined discontinuation date
Source sentences
Summary
Only 4912 (6.0%) individuals initiated follow-on therapy after discontinuation; mean time from discontinuation (last claim + 243 days) to follow-on therapy initiation was 3.3 months [SD = 3.4].
1 context sentence(design, population, supporting numbers)
Summary · context
During follow-up through 2022, we identified beneficiaries with follow-on osteoporosis therapy (i.e., oral and intravenous bisphosphonates, teriparatide, and abaloparatide) within 1 year after denosumab discontinuation.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4114388202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.